Rchr
J-GLOBAL ID:201801015816250361   Update date: Jul. 06, 2021

ken kato

カトウ ケン | ken kato
Affiliation and department:
Research field  (1): Tumor diagnostics and therapeutics
Papers (45):
  • Mitsumi Terada, Hiroki Hara, Hiroyuki Daiko, Junki Mizusawa, Tomohiro Kadota, Keisuke Hori, Hirofumi Ogawa, Takashi Ogata, Katsuyuki Sakanaka, Takeshi Sakamoto, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Japanese journal of clinical oncology. 2019. 49. 11. 1055-1060
  • Mitsumi Terada, Hiroki Hara, Hiroyuki Daiko, Junki Mizusawa, Tomohiro Kadota, Keisuke Hori, Hirofumi Ogawa, Takashi Ogata, Katsuyuki Sakanaka, Takeshi Sakamoto, et al. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). JAPANESE JOURNAL OF CLINICAL ONCOLOGY. 2019. 49. 11. 1055-1060
  • Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, et al. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Int J Clin Oncol. 2019. 24. 60-67
  • Shin Nishiumi, Seiji Fujigaki, Takashi Kobayashi, Takashi Kojima, Yoshinori Ito, Hiroyuki Daiko, Ken Kato, Hirokazu Shoji, Yuzo Kodama, Kazufumi Honda, et al. Metabolomics-based discovery of serum biomarkers to predict the side-effects of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Research. 2019. 39. 1. 519-526
  • Shuji Hiramoto, Ken Kato, Hirokazu Shoji, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Satoru Iwasa, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 2018. 23. 3. 466-472
more...
MISC (19):
  • Tomoya Yokota, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Hiroki Hara, Takashi Ura, Takashi Kojima, Keisho Chin, et al. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Annals of surgical oncology. 2020. 27. 2. 460-467
  • Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 2019. 20. 11. 1506-1517
  • Takao Iemoto, Shin Nishiumi, Takashi Kobayashi, Seiji Fujigaki, Tetsuya Hamaguchi, Ken Kato, Hirokazu Shoji, Yasuhiro Matsumura, Kazufumi Honda, Masaru Yoshida. Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. Oncology letters. 2019. 17. 1. 831-842
  • Madoka Nambu, Takeshi Masuda, Shingo Ito, Ken Kato, Takashi Kojima, Hiroyuki Daiko, Yoshinori Ito, Kazufumi Honda, Sumio Ohtsuki. Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer. Biological & pharmaceutical bulletin. 2019. 42. 10. 1766-1771
  • Seiji Fujigaki, Shin Nishiumi, Takashi Kobayashi, Makoto Suzuki, Takao Iemoto, Takashi Kojima, Yoshinori Ito, Hiroyuki Daiko, Ken Kato, Hirokazu Shouji, et al. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomarkers in medicine. 2018. 12. 8. 827-840
more...
Books (1):
  • 術前化学療法と術前化学放射線療法は,効果・安全性の面からどちらが良いか?
    医事新報社 2017
Lectures and oral presentations  (1):
  • A randomized controlled phase III comparing CF (5-FU, CDDP) versus DCF (5-FU, CDDP, docetaxel) versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer
    (International Symposium of Disease of Esophagus 2018)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page